| Hotline I - Cardiovascular risk and complications | |
 | PURE The prevention gaps in 17 low-, middle-, and high-income countries involving over 150,000 people Salim Yusuf, McMaster University, Hamilton, ON Presentation slides | Summary slide |
 | HCS Prospective evaluation of postprandial triglycerides and cardiovascular events in patients with coronary artery disease Ulrich Laufs, Universitätskliniken des Saarlandes, Homburg/Saar, Germany Summary slide |
 | dal-VESSEL Efficacy and safety of dalcetrapib in patients with or at risk of coronary heart disease Thomas Lüscher, University Zurich, Switzerland Summary slide |
 | ARISTOTLE |
 | CORP Colchicine for Recurrent Pericarditis: A multicenter, double-blind, randomized, controlled trial Massimo Imazio, Maria Vittoria Hospital, Turin, Italy Summary slide |
| Clinical Trial Update I - Drug treatment | |
 | ASCOT Anglo-Scandinavian Cardiac Outcomes Trial: 10 year follow-up of the Lipid_lowering Arml Professor Peter S Sever, Imperial College, London, GB Presentation slides |
 | ARISTOTLE Efficacy and safety of Apixaban compared to Warfarin at different levels of INR control for stroke prevention in 18,202 patients with atrial fibrillation in the ARISTOTLE trial Lars C. Wallentin, Uppsala, Sweden Presentation slides |
 | ROCKET AF Prevention of stroke and systemic embolism using the oral direct factor Xa inhibitor Rivaroxaban compared with Warfarin in patients with nonvalvular atrial fibrillation and moderate renal impairment Keith AA Fox, Edinburgh, Great Britain Presentation slides |
